Cericlamine (INN; developmental code JO-1017) is a potent and moderately selective serotonin reuptake inhibitor (SSRI) of the amphetamine family (specifically, a derivative of phentermine, and closely related to chlorphentermine, a highly selective serotonin releasing agent) that was investigated as an antidepressant for the treatment of depression, anxiety disorders, and anorexia nervosa by Jouveinal but did not complete development and was never marketed.[1][2][3][4] It reached phase III clinical trials in 1996 before development was discontinued in 1999.[5]
Clinical data | |
---|---|
Routes of administration | Oral[1] |
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 8 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H17Cl2NO |
Molar mass | 262.17 g·mol−1 |
3D model (JSmol) | |
| |
|
According to Czech scientists, cericlamine is claimed to be part of a highly advanced “fifth generation” of antidepressants as was venlafaxine.[6]
The daily dosage was reported to be 300mg.[1]
See also
editReferences
edit- ^ a b c d Darcourt G, Tessera M, Lesaunier R, Engrand P, Scherrer B, Dreyfus J, Bogaievsky Y (1992). "A Multicentre Double-Blind, Placebo-Controlled Dose-Finding Study with Cericlamine in Major Depression". Clinical Neuropharmacology. 15: 176B. doi:10.1097/00002826-199202001-00339. ISSN 0362-5664. S2CID 57983762.
- ^ Crow S, Brown E (March 2003). "Investigational drugs for eating disorders". Expert Opinion on Investigational Drugs. 12 (3): 491–9. doi:10.1517/13543784.12.3.491. PMID 12605570. S2CID 25463729.
- ^ Patel RM (3 January 2000). Stereoselective Biocatalysis. CRC Press. pp. 48–. ISBN 978-0-8247-8282-5.
- ^ Tang LC, Tang SJ (6 December 2012). Neurochemistry in Clinical Application. Springer Science & Business Media. pp. 81–. ISBN 978-1-4615-1857-0.
- ^ "Cericlamine". AdisInsight. Springer Nature Switzerland AG. Retrieved 13 January 2016.
- ^ Svestka, J. (1994). "Antidepressives of the 3rd, 4th and 5th generation". Ceskoslovenska Psychiatrie. 90 (1): 3–19. PMID 8174184.